PURPOSE: The aim of this study was to evaluate the activity and safety of oxaliplatin/5-fluorouracil-based chemo-radiotherapy in patients with not radically resectable locally advanced esophageal cancer. METHODS: Fifty-nine patients with adeno or squamous-cell carcinoma received oxaliplatin (60 mg/m(2)), and leucovorin (20 mg/m(2) on days 1,8,15,29,36,43,50,57) followed by continuous infusion fluorouracil (200 mg/m(2) per day on days 1-22 and 29-64) with radiotherapy (1.8 Gy daily fractions to a total dose of 45 Gy, from days 29 to 64). When feasible, surgery was scheduled 6-8 weeks after chemo-radiotherapy completion. The primary endpoint was 1-year progression-free survival. RESULTS: Forty (68%) patients completed treatment without modifications. An objective clinical response was seen in 35 patients (59%). Esophagectomy was possible in 33 patients and a complete resection (R0) was achieved in 26 (79%) with 6 pathologic complete responses (pCR) and 3 near pCR. At a median follow-up of 39.7 months for the surviving patients, the median progression-free and overall survivals were 11 months (95% CI 6.5-14) and 18.5 months (95% CI 13-29). The 1-year progression-free and overall survivals were 47.5% (95% CI 34-59.5%) and 63% (95% CI 49-74%). Major toxicities were esophagitis (20% G3 and 5% G4) and diarrhea (8.5% G3 and 8.5% G4). Hematological toxicity (7% G3 and 3% G4) was less common; severe neurotoxicity (3% G3) was infrequent. CONCLUSIONS: Concurrent oxaliplatin, leucovorin, fluorouracil and radiotherapy followed or not by esophagectomy has a tolerable toxicity and promising activity in locally advanced esophageal cancer.
PURPOSE: The aim of this study was to evaluate the activity and safety of oxaliplatin/5-fluorouracil-based chemo-radiotherapy in patients with not radically resectable locally advanced esophageal cancer. METHODS: Fifty-nine patients with adeno or squamous-cell carcinoma received oxaliplatin (60 mg/m(2)), and leucovorin (20 mg/m(2) on days 1,8,15,29,36,43,50,57) followed by continuous infusion fluorouracil (200 mg/m(2) per day on days 1-22 and 29-64) with radiotherapy (1.8 Gy daily fractions to a total dose of 45 Gy, from days 29 to 64). When feasible, surgery was scheduled 6-8 weeks after chemo-radiotherapy completion. The primary endpoint was 1-year progression-free survival. RESULTS: Forty (68%) patients completed treatment without modifications. An objective clinical response was seen in 35 patients (59%). Esophagectomy was possible in 33 patients and a complete resection (R0) was achieved in 26 (79%) with 6 pathologic complete responses (pCR) and 3 near pCR. At a median follow-up of 39.7 months for the surviving patients, the median progression-free and overall survivals were 11 months (95% CI 6.5-14) and 18.5 months (95% CI 13-29). The 1-year progression-free and overall survivals were 47.5% (95% CI 34-59.5%) and 63% (95% CI 49-74%). Major toxicities were esophagitis (20% G3 and 5% G4) and diarrhea (8.5% G3 and 8.5% G4). Hematological toxicity (7% G3 and 3% G4) was less common; severe neurotoxicity (3% G3) was infrequent. CONCLUSIONS: Concurrent oxaliplatin, leucovorin, fluorouracil and radiotherapy followed or not by esophagectomy has a tolerable toxicity and promising activity in locally advanced esophageal cancer.
Authors: Aminah Jatoi; Gamini Soori; Nathan R Foster; Bradley K Hiatt; James A Knost; Tom R Fitch; Matthew D Callister; Francis C Nichols; Tim M Husted; Steven R Alberts Journal: J Thorac Oncol Date: 2010-12 Impact factor: 15.609
Authors: M Orditura; G Galizia; N Di Martino; E Ancona; C Castoro; R Pacelli; F Morgillo; S Rossetti; V Gambardella; A Farella; M M Laterza; A Ruol; A Fabozzi; V Napolitano; F Iovino; E Lieto; L Fei; G Conzo; F Ciardiello; F De Vita Journal: Curr Oncol Date: 2014-06 Impact factor: 3.677
Authors: Somnath Mukherjee; Christopher N Hurt; Sarah Gwynne; Andrew Bateman; Simon Gollins; Ganesh Radhakrishna; Maria Hawkins; Jo Canham; Wyn Lewis; Heike I Grabsch; Ricky A Sharma; Wendy Wade; Rhydian Maggs; Bethan Tranter; Ashley Roberts; David Sebag-Montefiore; Timothy Maughan; Gareth Griffiths; Tom Crosby Journal: BMC Cancer Date: 2015-02-12 Impact factor: 4.430
Authors: Somnath Mukherjee; Christopher Nicholas Hurt; Sarah Gwynne; David Sebag-Montefiore; Ganesh Radhakrishna; Simon Gollins; Maria Hawkins; Heike I Grabsch; Gareth Jones; Stephen Falk; Ricky Sharma; Andrew Bateman; Rajarshi Roy; Ruby Ray; Jo Canham; Gareth Griffiths; Tim Maughan; Tom Crosby Journal: Eur J Cancer Date: 2017-02-08 Impact factor: 9.162
Authors: Xuan Sun; Robert C G Martin; Qianqian Zheng; Russell Farmer; Harshul Pandit; Xuanyi Li; Kevin Jacob; Jian Suo; Yan Li Journal: Cell Oncol (Dordr) Date: 2018-08-16 Impact factor: 6.730
Authors: William H Smith; Sofya Pintova; Christopher J DiMaio; Panagiotis Manolas; Dong-Seok Lee; Spiros P Hiotis; Maria Kartsonis; Randall F Holcombe; Kavita V Dharmarajan Journal: Case Rep Oncol Med Date: 2015-12-03